Pfizer Inc. $PFE Holdings Cut by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 6.2% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 332,178 shares of the biopharmaceutical company’s stock after selling 21,947 shares during the period. Sequoia Financial Advisors LLC’s holdings in Pfizer were worth $7,999,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. Norges Bank purchased a new stake in shares of Pfizer during the fourth quarter worth $1,830,986,000. Morgan Stanley increased its position in Pfizer by 19.2% in the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after purchasing an additional 14,342,946 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Pfizer by 38.9% during the 4th quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock worth $1,208,023,000 after purchasing an additional 13,581,757 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Pfizer by 577.5% during the 4th quarter. Janus Henderson Group PLC now owns 8,786,084 shares of the biopharmaceutical company’s stock valued at $218,817,000 after buying an additional 7,489,189 shares during the last quarter. Finally, Capital World Investors grew its stake in shares of Pfizer by 51.5% in the 4th quarter. Capital World Investors now owns 21,433,890 shares of the biopharmaceutical company’s stock valued at $533,704,000 after buying an additional 7,287,194 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PFE has been the topic of several recent research reports. Bank of America cut their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a research note on Tuesday, June 9th. Guggenheim cut their price target on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a report on Friday, August 7th. HSBC cut shares of Pfizer from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $32.00 to $28.00 in a report on Monday, July 6th. Finally, Citigroup raised their target price on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $28.28.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: CEO Albert Bourla purchased approximately $1 million of Pfizer stock—about 38,000 shares—in his first open-market purchase of the company’s shares. The transaction may reassure investors that management views the current valuation as attractive. Pfizer CEO Buys $1 Million of Company Stock
• Positive Sentiment: The European Medicines Agency validated Pfizer and Valneva’s application for their six-valent Lyme disease vaccine candidate, PF-07307405, beginning the formal review process. The filing is supported by Phase 3 results showing more than 70% efficacy and no significant safety concerns. Validation is an important regulatory milestone, although it does not represent approval. Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
• Positive Sentiment: An updated Korean real-world study of Paxlovid highlighted continued potential value for high-risk COVID-19 patients, supporting Pfizer’s effort to maintain demand for its antiviral as COVID-related revenue normalizes. Pfizer’s Korean Paxlovid Study Signals Ongoing Value in High-Risk COVID Market
• Neutral Sentiment: Erste Group Bank raised its fiscal 2026 EPS forecast, adding modest analyst support. Pfizer’s broader investment case also continues to rely on its non-COVID portfolio, including positive Phase 3 LITFULO data and recently acquired products.
• Negative Sentiment: Investors remain focused on Pfizer’s post-COVID revenue declines, recent intangible-asset impairments, and the discontinuation of its BEQVEZ hemophilia gene therapy, which underscore execution and pipeline risks. Gene Therapy Remains Top-of-Mind in Hemophilia

Pfizer Stock Performance

NYSE:PFE opened at $26.77 on Friday. The firm’s 50-day moving average is $25.12 and its 200-day moving average is $26.20. The company has a market cap of $152.60 billion, a price-to-earnings ratio of 35.23 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. Pfizer Inc. has a 52-week low of $23.58 and a 52-week high of $28.75.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter last year, the company earned $0.78 earnings per share. The firm’s revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.4%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is presently 226.32%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.